Literature DB >> 6974890

Significance of C-reactive protein elevation in the pretreatment stage of systemic lupus erythematosus.

T Inoue, Y Kanayama, N Katoh, A Ohe, K Amatsu, M Okamura, T Horiguchi.   

Abstract

The significance of C-reactive protein (CRP) elevation in patients with systemic lupus erythematosus (SLE) in the pretreatment stage was assessed with reference to other laboratory data obtained simultaneously. Sixteen of 31 cases were CRP-positive, and the CR-positive group contained significantly more cases with urinary cellular casts and with a high anti-DNA antibody titer, compared with the CRP-negative group. We suggest that CRP in patients with SLE, as measured at the time of the first consultation, reflects the severity of the disease. This includes those cases complicated by nephropathy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974890     DOI: 10.3109/03009748109095302

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  3 in total

1.  Differential diagnosis of fever in systemic lupus erythematosus using discriminant analysis.

Authors:  T Inoue; T Takeda; S Koda; N Negoro; M Okamura; K Amatsu; M Kohno; T Horiguchi; Y Kanayama
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

2.  Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Authors:  S P Ardoin; L E Schanberg; C Sandborg; E Yow; H X Barnhart; K l Mieszkalski; N T Ilowite; E von Scheven; A Eberhard; D M Levy; Y Kimura; E Silverman; S L Bowyer; L Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L K Jung; L Imundo; J B Soep; A M Reed
Journal:  Lupus       Date:  2010-10       Impact factor: 2.911

3.  Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations.

Authors:  P Betty Shih; Susan Manzi; Penny Shaw; Margaret Kenney; Amy H Kao; Franklin Bontempo; M Michael Barmada; Candace Kammerer; M Ilyas Kamboh
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.